Filing Flows › Roivant Sciences (ROIV) › Q3 FY25
Roivant Sciences (ROIV) Q3 FY25 earnings results (third quarter fiscal 2025)
10-Q filed Feb 10, 2025
Roivant Sciences (ROIV) reported revenue of $9.0M for the third quarter fiscal 2025 (Q3 FY25), -42% from a year earlier and +102% from the quarter before.
Roivant Sciences, Q3 FY25: revenue $9.0M (-42% year over year), net earnings $118M, operating cash flow −$207M. The chart follows the revenue to costs, profit and cash.
| Q3 FY25 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $9.0M | +102% | -42% |
| Operating profit | −$274M | — | — |
| Net earnings | $118M | — | — |
| Operating cash flow | −$207M | — | — |
What changed
Revenue was $9.0M in Q3 FY25, down 42% year over year and up 102% from the previous quarter.
Operating costs exceeded revenue by $274.4M, an operating margin of -3042.6%. Net earnings were $169.4M, down 97% year over year ($118.1M including minority interests, which bore $51.3M of losses). The effective tax rate was -27.6%. Non-operating items added $366.9M, 397% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$207.3M. Non-cash charges added back $2.9M of depreciation and amortization and $83.7M of share-based compensation. Working capital and other items used $411.9M. Capital expenditures of $1.8M exceeded it, leaving free cash flow of −$209.1M.
Questions
What was Roivant Sciences' revenue in the third quarter fiscal 2025?
Roivant Sciences (ROIV) reported revenue of $9.0M for the third quarter fiscal 2025 (Q3 FY25), -42% from a year earlier and +102% from the quarter before.
Source: Roivant Sciences 10-Q on SEC EDGAR.